Progastrin releasing peptide (ProGRP)

ProGRP Antibody

Name	Anti- Progastrin releasing peptide (ProGRP) antibody
Platforms	Chemiluminescence immunoassay (CLIA)
Catalog #	R256t6
Usage	Detection/Capture
Description	Mouse monoclonal antibody, cultured in vitro
Buffer	1 x PBS, pH 7.4
Purity	Purity>95%, purified by Protein A/G chromatography
Storage	Aliquot and store at -20°C or lower. Avoid freeze / thaw cycles.

ProGRP Antigen

Name	Progastrin releasing peptide (ProGRP) antigen
Description	Recombinant, C-terminal His-tagged, in vitro expressed from E.coli cells
Applications	Calibrator and quality control product
Catalog #	C1550
Purity	>90%, analyzed by R250-stained SDS-PAGE
Buffer	1 x PBS，pH 7.4
Storage	Aliquot and store at -80°C. Avoid freeze / thaw cycles.
SDS-PAGE	Predicted MW around 14 kDa

Product Information

Updating

Introduction to Progastrin releasing peptide (ProGRP)

Progastrin releasing peptide (ProGRP) is the precursor of gastrin releasing peptide (GRP). It is the initial product encoded by the GRP gene and is commonly found in nerve fibers, non-gastric antral tissues, neuroendocrine cells of the brain and lungs.
ProGRP can be alternatively spliced to produce three isoforms with a common C-terminal sequence and can be stably expressed in plasma. At present, ProGRP has high sensitivity and specificity to small cell lung cancer (SCLC) as a tumor marker, and it is also an important factor for the early diagnosis, prognostic and curative effect analysis of SCLC. ProGRP does not produce or produces very little in benign and other non-small cell lung cancers or lung lesions, thus makes it a high diagnostic value for SCLC. Studies have shown that the specificity of ProGRP for diagnosing SCLC is up to 88.89%, and the sensitivity is 63.16% for early stage SCLC. The combined detection of ProGRP, NSE, CYFRA21-1 and other indicators will help to further improve the diagnostic accuracy for small cell lung cancer.

Reference

[1] Oremek GM, Sapoutzis N. Pro-gastrin-releasing peptide(Pro-GRP), a tumor marker for small cell lung cancer [J]. Anticancer Research. 2003, 23(2): 895- 898.